Drug Discovery & Development | FDA Accepts NDA for Gilead Lymphoma Drug Drug Discovery & Development 11, 2013, was supported by a single arm Phase 2 study (Study 101-09) evaluating idelalisib in patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. Following Gilead's NDA submission for ... US FDA Accepts New Drug Application for Gilead's Idelalisib for the Treatment ... |
